Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

An Overview on the Development of New Potentially Active Camptothecin Analogs Against Cancer

Author(s): Eliza de Lucas Chazin, Raisa da Rocha Reis, Walcimar Trindade Vellasco Junior, Lucas Fajardo Elmor Moor and Thatyana Rocha Alves Vasconcelos

Volume 14, Issue 12, 2014

Page: [953 - 962] Pages: 10

DOI: 10.2174/1389557514666141029233037

Price: $65

Abstract

Camptothecin (CPT) and its derivatives comprise an important group of heterocyclic compounds that are well recognized for their anticancer activities. Efforts have been made over the years aiming to develop new CPT analogs with better clinical efficacy, improved pharmacokinetic profile and lower toxicity. First generation of analogs, irinotecan (CPT-11) and topotecan (TPT) was approved for use by FDA in 1996 for the treatment of colorectal (CPT-11) and cervical, ovarian and small lung cancers (TPT). Other analogs of CPT are currently in different phases of clinical trials. As CPT represents an important lead compound in the field of antitumor- research, in this review we will highlight some recent discoveries (2008-2013) on the development of novel camptothecin-based compounds as potential anticancer agents.

Keywords: Camptothecin, cancer, drugs, homocamptothecin, irinotecan, topoisomerase inhibitors, topotecan.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy